My latest with the @nymedcollege @WMCHealth neuroscience team: Levetiracetam was associated with reduced risk of early seizures (<7 days) among severe TBI patients (GCS 3-8), but did not protect from early seizures after mild TBI, or from late post traumatic epilepsy (<1 year). These results are very similar to the landmark Temkin paper looking at phenytoin prophylaxis after severe TBI. Levetiracetam for Seizure Prophylaxis after Traumatic Brain Injury: A Severity‐Stratified Cohort Study of 51,000 Patients @AnnalsNeuro onlinelibrary.wiley.com/doi/…

New Article! A generic, rapid and robust platform for personalized functional circuit-guided neuromodulation targeting dlvr.it/TSldsD

We have some of the best technologists in the world - experts in their craft and exceptional teammates. The team brought in breakfast on Dr. Snehal’s last day of IONM rotation, a sweet gesture that reflects the culture of teamwork, support and camaraderie #mayoneurofellowships

What brain circuits do we need to target to improve symptoms of bipolar disorder? With support from @BD2Discoveries our team of psychiatrists, neurologists, neurosurgeons, and neuropsychologists will find out! @Brain_Circuits @MGBResearchNews

Scientists at Oxford University have demonstrated, for the first time, that a key emotional centre deep in the human brain directly influences how we interpret ambiguous social cues. Find out more ⬇️ ox.ac.uk/news/2026-04-02-oxf…

Congratulations @shansiddiqi and Joe Taylor @Brain_Circuits on their paper in @molpsychiatry demonstrating the translational power of LNM and brain circuit therapeutics. It has already changed clinical TMS practice @BrighamWomens @harvardmed.

This work shows high semiologic concordance in SEEG stimulation-induced seizures compared to spontaneous seizures. doi.org/10.1002/epi4.70221 #Epilepsy #ILAE #epilepsiaopen #epilepsy #SEEG #seizure #semiology #stimulation

In the Human Epilepsy Project multicenter cohort study, most individuals with newly diagnosed focal #epilepsy required over a year and multiple antiseizure medications to become seizure free. ja.ma/43vP03Q

A true pioneer in the field of neurophysiology & EEG. What a loss! Every EEGer should read this classic paper by Klass and Westmoreland. onlinelibrary.wiley.com/doi/… #NeuroX #Epilepsy #Neurophysiology

"By redefining Parkinson’s as a SCAN disorder, we can shift our focus from treating a scattered collection of symptoms to addressing the core circuit pathology." ✍️Jianxun Ren (@DavidRen555), PI at Changping Laboratory 🔗daily27.info/2026/03/16/reth… #Health #Brain #Parkinson #News

New study from Jefferson Neurosurgery: Deep Brain Stimulation has LOWER complication rates than knee replacement, hip replacement & hysterectomy. If DBS has been recommended, the risk is less than you think. onlinelibrary.wiley.com/doi/…

Thrilled to announce our new paper in @NatureNeuro ! We managed the impossible: precision functional mapping during #DBS, with 11.7h fMRI/patient. Selective DBS-induced deactivations in the SCAN, building on our recent @Nature paper. @hesheng3 @iamzhangvv nature.com/articles/s41593-0…

Excellent new paper from Jiang lab demonstrating hippocampal modulation via inferior parietal lobe TMS.

Familial Epilepsy Is Not as Simple as We Think | Beyond the Ion Channel ...we just published a post on our Epilepsia study of genetic testing in 484 families. Familial epilepsy has a strong genetic yield, but pedigree patterns can be misleading. epilepsygenetics.blog/2026/0…

Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease #algorithm #adaptive #DBS #deepbrainstimulation #programming #PD #Parkinson March 2026 PRD

Surgery led to seizure freedom in 64.61% of patients with PMG-related drug-resistant epilepsy. doi.org/10.1002/epi4.70217 #epilepsy #ILAE #epilepsiaopen #neuropsychologicalassessment #pediatricepilepsy #PMG #qualityoflife #surgicaloutcomes

Japan just approved stem cells for Parkinson’s disease. How will it work? Stem cells are special cells that can develop into other types of cells. In this case they are turned into dopamine-producing brain cells designed to replace the cells lost in Parkinson’s disease. Sawamoto and colleagues described in a new paper in Nature one of the first phase I/II clinical trial using induced pluripotent stem cell derived dopaminergic progenitor cells transplanted into the brains of folks living w/ Parkinson’s disease. These cells are generated from iPS cells and implanted into the putamen where dopamine neurons normally function. Key Points: - Seven folks w/ Parkinson’s disease received bilateral transplantation of dopaminergic progenitor cells derived from iPS cells into the putamen and were followed for 24 months. - The transplanted cells survived, produced dopamine, and imaging revealed a roughly 44 percent increase in dopamine related activity in the putamen. - The procedure appeared safe w/ no tumors or graft overgrowth and several participants experienced improvements in motor scores on Parkinson’s rating scales. My take: Japan has a unique regulatory pathway for regenerative medicine that allows conditional approval once safety and early signals of benefit are demonstrated. For the therapy to advance in Japan data will be collected over the next 7 years. This paper represents an important milestone because it shows that lab grown dopamine cells can survive in the human brain and begin producing dopamine. The big questions ahead will be durability, patient selection, and whether the next 7 years of experience will confirm meaningful and sustained clinical benefit. Here are 5 points that resonated w/ me: 1- Parkinson’s disease is caused by the loss of dopamine producing neurons and this therapy attempts to replace those missing cells. 2- The transplanted cells are generated from induced pluripotent stem cells which are adult cells reprogrammed to behave like embryonic stem cells. 3- Brain imaging revealed new dopamine activity in the transplanted region suggesting the cells were functioning. 4- Safety remains the first hurdle and this trial showed no tumors or uncontrolled cell growth over two years of follow up. 5- The future will likely combine cell therapy w/ medications, rehabilitation, and possibly gene therapy to maximize benefit for folks living w/ Parkinson’s disease. Here is the Nature paper that set the stage for the recent approval. nature.com/articles/s41586-0… #parkinson @ParkinsonDotOrg @FixelInstitute

Should residents & fellows bill? A single resident can provide >$300k/yr in uncompensated care due to outdated @CMSGov rules. Our @NEJM paper proposes a competency-based framework to capture this revenue, improve trainee pay, and offset massive debt. #MedTwitter #MedEd #GME

Pls check out our latest article on #sEEG-guided #radiofrequency #thermocoagulation in #epilepsy, featuring a new FDA-approved #electrode technology! So great to have another tool for improving patient care! Initial clinical experience with the first FDA-approved sEEG-guided radiofrequency ablation system featuring real-time temperature monitoring: karger.com/sfn/article/doi/1… #epilepsysurgery #networks #brain #RFTC #ablation @NeuroKarger @ASSFNeurosurg @DynectomeLab

Mark this day as a major turning point for #Dravet syndrome and the treatment of #epilepsy in general! Today the New England Journal of Medicine published results from @StokeTx phase 1/2 studies of zorevunersen demonstrating evidence of impressive seizure reduction on top of best standard of care AND improvements in non-seizure outcomes such as communication in children with Dravet! The era of disease modification is upon us for genetic epilepsies and this is just the beginning! nejm.org/doi/full/10.1056/NE…